Summary
ESPR Chart
Esperion Therapeutics Inc. Dividends
Esperion Therapeutics Inc. Earnings
| 5 May 2025 (15 Days) Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 5 May 2025 (15 Days) Date | | - Cons. EPS | - EPS |
| 25 Feb 2025 Date | | - Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
Esperion Therapeutics Inc. (ESPR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Esperion Therapeutics Inc. ever had a stock split?
Esperion Therapeutics Inc. Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Sheldon L. Koenig CEO | NASDAQ (NMS) Exchange | US29664W1053 ISIN |
| United States Country | 240 Employees | - Last Dividend | - Last Split | 26 Jun 2013 IPO Date |
Overview
Esperion Therapeutics, Inc. is a pioneering pharmaceutical company specialized in the development and commercialization of innovative medicines designed to combat elevated levels of low-density lipoprotein cholesterol (LDL-C). Established in 2008 and rooted in Ann Arbor, Michigan, Esperion has established itself as a key player in addressing hyperlipidemia, a major risk factor for cardiovascular diseases. Through strategic license and collaboration agreements with global pharmaceutical powerhouses such as Daiichi Sankyo Co. Ltd, Otsuka Pharmaceutical Co., Ltd, and Daiichi Sankyo Europe GmbH, Esperion enhances its capabilities to bring its novel treatment options to a broader patient population worldwide.
Products and Services
- NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets
- NILEMDO
- NUSTENDI
These oral, once-daily, non-statin medicines are developed by Esperion for the treatment of primary hyperlipidemia in adults. They are particularly targeted at patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who need an additional reduction in LDL-C levels. By offering a non-statin alternative, these products provide a solution for patients who may not tolerate statin therapies well.
An innovative ATP Citrate Lyase (ACL) inhibitor, NILEMDO significantly lowers LDL-C and cardiovascular risk by impeding cholesterol biosynthesis and enhancing the up-regulation of LDL receptors. This product stands out for its direct action on cholesterol production pathways, offering a novel mechanism of action in the fight against hyperlipidemia.
A combination of bempedoic acid and ezetimibe, NUSTENDI is formulated to target elevated LDL-C. It offers a dual mechanism of action by not only inhibiting cholesterol biosynthesis (via bempedoic acid) but also reducing intestinal cholesterol absorption (via ezetimibe). This synergistic action makes NUSTENDI a potent option for patients requiring comprehensive LDL-C management.
Contact Information
